Ardelyx (ARDX) Q3 2026 Earnings Call Transcript

Ardelyx reported Q3 2026 product revenue of $125.5 million, up 19% year over year, including IBSRELA revenue of $96.3 million (+23%) and XPHOZAH revenue of $29.2 million (+7%); net loss narrowed to $700,000 from $1 million. The company reaffirmed 2026 revenue guidance of $350–$370 million for IBSRELA and $110–$120 million for XPHOZAH, with operating expenses expected below $500 million, and said it continues to target profitability in 2027. Cash and investments totaled $285.3 million, while ACCEL Phase III enrollment finished ahead of schedule, with top-line results planned for the second half of 2027; management cited dialysis reimbursement complexity and customer buying patterns as risks for XPHOZAH.

Analysis

ARDX’s key debate is revenue quality, not demand. IBSRELA’s growth can compound if the pharmacy network converts more prescriptions into completed fills and repeat use, but management withheld network penetration and says script data will become less directly comparable as channel mix shifts. DTC traffic and ad-test intent are leading indicators, not evidence yet of incremental paid starts; broader promotion may also raise reimbursement workload and SG&A before it lifts revenue. Watch paid prescriptions, fills, gross-to-net and spend together.

XPHOZAH’s paid-script growth outpacing revenue growth is a caution on translating demand into sales: customer purchasing patterns and the dialysis reimbursement transition cloud the read-through. The end of TDAPA is the key 2027 catalyst, but also a downside risk if post-transition economics weaken. Avoid treating one quarter’s inventory explanation as proof of normalized sell-through.

Near term, the reaffirmed outlook and near break-even quarter support sentiment, but 2027 profitability remains execution-dependent: rising gross-to-net, commercial investment and R&D can absorb the benefit of high product gross margins. ACCEL is a distant, binary 2H27 catalyst, not a near-term valuation anchor. The claimed patent extension is not yet issued as of this call; verify issuance, claim scope and relevant listing before assigning durable exclusivity value.

Contrarian view: the market may over-credit reported demand and underweight access friction and net pricing. Conversely, a noisy XPHOZAH quarter alone is insufficient evidence of deterioration. Without valuation and channel-level data, the earnings signal supports a conditional long bias rather than chasing ARDX at the open.

Key Decisions for Investors

• Do not chase ARDX on the call alone. Consider a staged long on weakness only if subsequent data show IBSRELA paid prescriptions and completed fills translating into revenue, with gross-to-net not materially worsening; reassess if guidance is cut or access costs rise without fill improvement.
• Track IBSRELA network penetration, paid-start conversion, refill behavior, gross-to-net and SG&A as a single dashboard. Treat website traffic and stated IPN fulfillment advantages as unverified commercial indicators until management provides trend data.
• Keep XPHOZAH exposure catalyst-aware: wait for clearer post-TDAPA reimbursement and sell-through evidence before underwriting renewed growth. A further revenue/script divergence or weaker reimbursement outlook would falsify the normalization thesis.
• Do not capitalize the expected patent issuance or ACCEL success as established value today. Verify patent issuance and scope; treat ACCEL top-line data in 2H27 as a separate, high-variance catalyst.